Loading

Benicar

By E. Milok. North Georgia College and State University, the Military College of Georgia. 2019.

Once a product has been authorised as a biosimilar by the regulators generic 10mg benicar fast delivery, it should be considered by the prescriber as therapeutically equivalent in its authorised indications purchase 10mg benicar fast delivery. Since the approval of the first biosimilar (Omnitrope® cheap 20mg benicar visa, a somatropin biosimilar to Genotropin®) in 2006 buy cheap benicar 20mg on-line, until mid-2015, twelve biosimilar medicines have been authorised under 19 brand names in six types of product: somatropin, filgrastim, 15 epoetin alfa, infliximab, follitropin alfa and insulin glargine. Once authorised by the European Commission, biosimilars are subject to the same level of post-authorisation regulatory scrutiny as originator (reference) products and will pursue their own development (e. The decision regarding the choice of biosimilar or originator biological medicine for an individual patient rests with the responsible clinician in consultation with the 18 patient. Competition between different biological medicines, including biosimilar medicines, creates increased choice for patients and clinicians, and enhanced value 19 propositions for individual medicines. Biosimilar medicines are more challenging and expensive to develop than generic 21 medicines. Whilst they cannot offer the same percentage price reductions as traditional generic medicines, nevertheless, there are significant savings associated with increased competition between biological medicines, including biosimilar medicines. Recent research has given clear evidence that the additional competition is bringing 22 value and opportunity to widen access for patients in some circumstances. However, this research also demonstrates that biosimilar medicine uptake across Europe to date shows very different patterns, depending on the class of biological medicine and the procurement measures in place. Biosimilar medicines are approved to be therapeutic equivalents to the reference medicine, establishing that the previously proven safety and efficacy of that medicine 24 also applies to the biosimilar. As with any biological medicine, the biosimilar medicine will have details of its licensed indications included in the British National Formulary. Those making decisions about whether to purchase a biosimilar should consider the 25 following questions:  Is the biosimilar licensed for all the indications and routes of administration required? Treatment decisions should be made first on the basis of clinical judgement for individual patients and secondly on the basis of the overall value proposition offered by individual medicines. The role of the physician in treating patients with these complex medicinal products is 27 particularly important. Patient consultation, which takes into account their needs, preferences and values, is also an essential part of evidence-based medicine. Clinicians should seek to use all 28 available evidence to guide decisions about the care of the individual patient. Evolving 30 evidence and treatment guidance should be made available to patients and prescribers to support them in their decision-making. Automatic substitution, defined here as the practice of dispensing one medicine instead of another equivalent and interchangeable medicine at the pharmacy level 31 without consulting the prescriber, is not appropriate for biological medicines, including biosimilar medicines and is not permitted at this time. Prescribers, of course, are always able to switch treatments for a given patient, provided it is safe to do so and there are appropriate monitoring arrangements in place. It is important to ensure that prescribers are aware of the different requirements associated with biological medicines, including biosimilar medicines (as well as some other products). Measures should be taken to ensure all those involved in the prescribing and dispensing of such medicines abide by these requirements, such as brand name prescribing. Q: Where can I find further Once placed on the market they continue to be information on safety of monitored by all relevant stakeholders to assure biological medicines? In different to the reference medicine addition, the companies marketing biosimilars have been identified for biosimilars. Medicines under additional monitoring have a black inverted triangle (▼) in their labelling. An inability to attribute any safety concerns to the correct product, manufacturer and 41 batch could prevent a root-cause determination and may put patients at risk. This variation is kept within strict acceptable limits, which is monitored by the manufacturer and approved by the regulator, known as ‘release specifications’. Some of them may be present in the human body and examples include proteins such as insulin and growth hormone. Active substances in biological medicines are larger and more complex than those of non- 44 biological medicines. A candidate molecule is designed, produced and compared with several batches of the reference (originator) medicine using advanced analytical techniques to assess its structure and function. It must be shown to match or be highly similar to the key characteristics of the molecular structure and biological activity, and will be expected to have similar function and clinical outcome. Any differences will be expected to have no meaningful clinical impact on the safety and efficacy of the medicine for patients. The manufacturer must ensure the process is controlled and the variability remains within release specifications approved by the regulatory authority. The assessment for any manufacturing change is done via a comparability exercise, informed by the historical manufacturing, non-clinical and clinical data available to the manufacturer. Depending on the scale of the change and the potential impact to the product, the regulator may ask for additional analytical data, non-clinical and clinical data, but the aim is to ask only for what is needed to make an assessment. If they contain more than one atom, the atoms can be the same (an oxygen molecule has two oxygen atoms) or different (a water molecule has two hydrogen atoms and one oxygen atom). Biological molecules, such 51 as proteins, can be made up of many thousands of atoms. Please refer to the European Medicine Agency’s website for the latest list of biosimilars authorised in Europe, as there are many other biosimilar products in development. The ability to make appropriate diagnostic and management decisions that have important consequences for patients will be assessed. The exam may require recognition of common as well as rare clinical problems for which patients may consult a certified internist. Exam content Exam content is determined by a pre‐established blueprint, or table of specifications. Trainees, training program directors, and certified practitioners in the discipline are surveyed periodically to provide feedback and inform the blueprinting process. The primary medical content categories of the blueprint are shown below, with the percentage assigned to each for a typical exam: Medical Content Category % of Exam Allergy and Immunology 2% Cardiovascular Disease 14% Dermatology 3% Endocrinology, Diabetes, and Metabolism 9% Gastroenterology 9% Geriatric Syndromes 3% Hematology 6% Infectious Disease 9% Nephrology and Urology 6% Neurology 4% Obstetrics and Gynecology 3% Medical Oncology 6% Ophthalmology 1% Otolaryngology and Dental Medicine 1% Psychiatry 4% Pulmonary Disease 9% Rheumatology and Orthopedics 9% Miscellaneous 2% Total 100% Every question in the exam will fall into one of the primary medical content categories shown above. There are also other important areas that are addressed in conjunction with this medical content, and these areas are called “cross content categories. Questions ask about the work done (that is, tasks performed) by physicians in the course of practice:  Making a diagnosis  Ordering and interpreting results of tests  Recommending treatment or other patient care  Assessing risk, determining prognosis, and applying principles from epidemiologic studies  Understanding the underlying pathophysiology of disease and basic science knowledge applicable to patient care Clinical information presented may include patient photographs, radiographs, electrocardiograms, recordings of heart or lung sounds, and other media to illustrate relevant patient findings. The primary medical categories can be expanded for additional detail to show topics that may be covered in the exam. Each primary medical content category is listed below, with the percentage of the exam assigned to this content area. Below each major category are subsection topics and their assigned percentages in the exam. Please note: The percentages below describe content of a typical exam and are approximate; actual exam content may vary. Investigations led to the knowledge how bacteria, fungi, and viruses are used to treat ailments ranging from colon cancer to malaria.

benicar 40 mg line

discount 10 mg benicar

The reason for the observed racial differences in the age at which girls enter puberty is unknown order benicar 40mg otc. The onset of the growth spurt in girls begins before the onset of breast devel- opment (Tanner trusted benicar 40 mg, 1990) purchase 20mg benicar free shipping. All children continue to grow to some extent until as late as age 20 years generic 20 mg benicar amex; therefore, having these two age categories span the period of 9 through 18 years of age seems justified. Young Adulthood and Middle-Aged Adults: Ages 19 Through 30 Years and 31 Through 50 Years The recognition of the possible value of higher nutrient intakes dur- ing early adulthood on achieving optimal genetic potential for peak bone mass was the reason for dividing adulthood into ages 19 through 30 years and 31 through 50 years. Moreover, mean energy expenditure decreases during this 30-year period, and needs for nutrients related to energy metabolism may also decrease. Adulthood and Older Adults: Ages 51 Through 70 Years and Over 70 Years The age period of 51 through 70 years spans the active work years for most adults. After age 70, people of the same age increasingly display variability in physiological functioning and physical activity. This is demonstrated by age-related declines in nutrient absorption and renal function. This variability may be most applicable to nutrients for which require- ments are related to energy expenditure. Pregnancy and Lactation Recommendations for pregnancy and lactation may be subdivided because of the many physiological changes and changes in nutrient need that occur during these life stages. Moreover, nutrients may undergo net losses due to physi- ological mechanisms regardless of the nutrient intake. Reference Heights and Weights Use of Reference Heights and Weights Reference heights and weights are useful when more specificity about body size and nutrient requirements are needed than that provided by life stage categories. In some cases, where data regarding nutrient requirements are reported on a body-weight basis, it is necessary to have reference heights and weights to transform the data for comparison purposes. Frequently, where data regarding adult requirements represent the only available data (e. Besides being more current, these new reference heights and weights are more representative of the U. In addition, to provide guidance on the appropriate macronutrient distribution thought to decrease risk of disease, including chronic disease, Acceptable Macronutrient Distribution Ranges are established for the macronutrients. These reference values have been developed for life stage and gender groups in a joint U. It also provides recommendations for physical activity and energy expenditure to maintain health and decrease risk of disease. Secondary sexual characteristics and menses in young girls seen in office practice: A study from the Pediatric Research in Office Settings Network. Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride. Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chro- mium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. Studies in human lactation: Milk volumes in lactating women during the onset of lactation and full lactation. Randomized trial of varying mineral intake on total body bone mineral accretion during the first year of life. Specific subcomponents, such as some amino acids and fatty acids, are required for normal growth and development. Other subcomponents, such as fiber, play a role in decreas- ing risk of chronic disease. For example, under normal circumstances the brain functions almost exclusively on glucose (Dienel and Hertz, 2001). To a large extent, the body can synthesize de novo the lipids and carbohydrates it needs for these specialized functions. An exception is the requirement for small amounts of carbohydrate and n-6 and n-3 poly- unsaturated fatty acids. Otherwise, there are no specific “dietary require- ments”1 for fat or carbohydrate for specific functions. Of course, some mixture of fat and carbohydrate is required as a source of fuel to meet the energy requirements of the body. It was also necessary to provide quantitative guidance on propor- tions of specific sources of required energy based on evidence of decreased risk of disease (which, in most cases, is chronic disease). Thus, a fundamental question to be addressed when reviewing the role of these nutrients in health is, What is the most desirable mix of energy sources that maximizes both health and longevity? Because indi- viduals can live apparently healthy lives for long periods with a wide range of intakes of specific energy nutrients, it is not surprising that this optimal mix of such sources may be difficult to define. There are no clinical trials that compare various energy sources with longevity in humans. For this reason, recommendations about the desirable composition of energy sources must be based on either short-term trials that address specific health or disease endpoints, or surrogate markers (biomarkers) that cor- relate well with these endpoints. A large number of research studies have been carried out to examine the effects of the composition of energy sources on surrogate markers, and these have provided a basis for making recommendations. Because diets with specific ratios of carbohydrate to fat, or specific ratios of subcomponents of each, have associations with the risk of various clinical endpoints (e. For any given diet consumed by an individual, the sum of the contribution to energy intake as a percentage of total intake for carbohydrate, fat, protein, and alcohol must equal 100 percent. The acceptable range of macronutrient intake is a range of intakes for a particular nutrient or class of nutrients that will confer decreased risk of disease and provide the most desirable long-term health benefits to apparently healthy individuals. Basic biological research, often involving animal models, provides critical information on mechanisms that may link nutrient consumption to beneficial or adverse health outcomes. Experimental studies include randomized and nonrandomized therapeutic or preven- tion trials and controlled dose–response, balance, turnover, factorial, and depletion–repletion physiological studies. Clinical and epidemiological observational studies play a valuable role in generating hypotheses con- cerning the health risks and benefits of nutrient intake patterns. Random- ized clinical trials in population groups of interest have the potential to provide definitive comparisons between selected nutrient intake patterns and subsequent health-related outcomes. Note, however, that randomized trials attempting to relate diet to disease states also have important limita- tions, which are elaborated in the discussion below. Animal Models Basic research using experimental animals affords considerable advan- tage in terms of control of nutrient exposures, environmental factors, and even genetics. In addition, dose levels and routes of administration that are practical in animal experiments may differ greatly from those relevant to humans. Human Feeding Studies Controlled feeding studies, usually in a confined setting such as a metabolic unit, can yield valuable information on the relationship between nutrient consumption and health-related biomarkers. Much of the under- standing of human nutrient requirements to prevent deficiencies is based on studies of this type. Studies in which the subjects are confined allow for close control of intake and activities and complete collection of nutrient or metabolite losses through urine and feces.

However purchase 10 mg benicar otc, for a number of artifcially e e induced isotopes positron emission takes place cheap benicar 10 mg on line. The fate of the emitted positron is 40 mg benicar sale; after Illustration of the annihilation being slowed down order benicar 20 mg otc, it will meet an elec- tron, and then either annihilate directly, or 511 keV photon form a short-lived “positronium atom”. The fnal process is an annihilation where the mass of the two particles is trans- formed into g-ray photons. A very important point is that the photons fy off in opposite directions (see the illustration to the right). We observe the two photons by detectors 180 degrees apart (coincidence measurements). We know Courtesy of Arnt Inge Vistnes from this observation that the annihilation process has taken place somewhere along the line shown in the illustration. One coincidence observation yield a line whereas two or more observations in other directions give a point (or a small area) where the radioactivity has its origin. Information on how tissue and organs functions on both the molecular and cell level. It is also possible to study changes in the brain that follows Alzheimer disease and epilepsy. Positron and positronium In connection to positron emission – we have to mention the “atom” positronium. When the positron has lost its kinetic energy and meet an electron, it is a possibility that they will exist for a short mo- ment almost like an atom (see illustration). It can be mentioned that the frst theoretical work on positro- nium was carried out by Aadne Ore in 1949. Ore was con- nected to the group of biophysics at the University of Oslo – in fact he was the one that started this group. Positronium can be either orto-positronium (parallel spins) or para-positronium (opposite spin). Aadne Ore Para-positronium decays in two photons, both with energy (1916 – 1980) 511 keV whereas orto-positronium decays in three photons (combined energy is 1. Modell av Positronium Ore published the work in two articles; “Annihilation of Positrons in Gases” and “Ortho-Parapositronium conversion”. Coinsidences for two opposite detectors are measured and a picture is recon- structed. The isotopes must be hooked on special chemicals that can transport the positron emitter to places of interest. C – 11 connected to acetate has been proposed as a tracer for prostate tumor cells. The use of F-18 F-18 can be made in a cylotron by irradiating O-18 enriched water with protons. The reaction can be written: 18 18 O +=p F +n 8 9 After the production of F-18 we have to work fast since the halfife is only a couple of hours. We know that the active cancer cells need more sugar than other cells in the body. There- fore, we hook on F-18 to glucose – and the sugar molecule will transport F-18 to the active cells – the cancer cells. Photons with energy 511 keV are measured in coinsidence by detectors 180 degrees from each other. Two different tumors were localized; a sarcoma in the right scapula (shoulder blade) and a lymphoma in the right axillary lymph. The cancers were treated by radiation and the result is seen on the series of pictures – the sarcoma to the left and the lymphoma to the right. You see that the large sarcoma in the right scapula is radioresistant – independent of the radiation dose given. The lymphoma in the right axillary lymph is however radiosensitive and is eliminated after a dose of 40 Gy. The images were taken before the start of radiotherapy (0 Gy), after 8 Gy (early treatment) and after 40 Gy (late treatment). For these methods no ionizing radiation is involved and no absorbed or scattered photons are making the pic- tures. However, Raymond Damadian in spite of this it was a sensation (born 1936) and a start of a technique that to- (photo from 2009) day is very important within med- ical diagnostics. The Nobel prize in physics for 1952 was awarded to Bloch and Purcell for nuclear magnetic resonance. Yevgeny Zavoisky Felix Bloch Edward Mills Purcell (1907 – 1976) (1905 – 1983) (1912 – 1997) 204 The physics of magnetic resonance In this book we are interested in the physical background for the different medical techniques rather than to the techniques themselves. Knowledge about x-rays and radioactive nuclides was important for the methods discussed so far. In the case of the electron it can be written as: Here b is the Bohr-magneton, S is the electron spin and “g“ is the spectroscopic splitting factor – which for free electrons is 2,0023. If these small magnets are placed in a magnetic feld B, they will attain an energy which depends on the spin state. B S S where mS is the spin quantum number for the electron, which can have two values; +1/2 and –1/2. The reonance phenomenon +1/2gbB Energy difference: hn = gbB –1/2gbB Increasing magnetic feld 205 The fgure show that all the small magnets have equal energy as long as the external magnetic feld is zero. However, in a magnetic feld the magnets will be oriented “with” or “against” the magnetic feld. The two states have different energies – and the energy difference increases with the feld B as shown. It is possible to induce transitions between the energy states by electromagnetic radiation. The condition for inducing transitions between the energy states is that the energy of the radiation (hn) is equal to the energy difference. The condition for an absorption can be written: hn = gbB for electrons and hn = g b B for protons N N The fgure indicates that we can have resonance at any given frequency as long as the magntic feld follows the resonance condition. However, it is a big difference since gb for electrons is much larger than g b for protons. The electromagntic radiation yields transitions in both directions with the same probability. Thus, if the populations of the two levels is equal, the net result would be nil – neither absorption, nor emis- sion. The population of the states follows a Boltzman distribution with the lowest level most popu- lated. In order to have a constant absorption, the difference in population must be kept. It appears that these relaxation times changes when going from normal to pathological tissue – and this can be used in diagnostics.

Support PUT

General Donations

Top Sponsors

Social

Like Us